Gal Noyman Veksler
Principal @ LionBird
Gal Noyman Veksler is a seed investor at LionBird focused on Wellness and Health Care. Gal Noyman Veksler Gal previously co-founded and served as CEO of NeuroLabs AI, an opioids dependence prevention platform, tackling the opioid epidemic through ongoing assessment of pain and mood symptoms at home. Gal also previously served as VP Business Development and Director of Healthcare at a multinational AI expert firm, and as an investmentanalyst at aMoon, the largest venture capital fund in Israel.Gal holds a PhD in Clinical and NeuroPsychology in chronic pain (for which she was awarded the national Wolf Scholarship) and has frequently published in top tier medical journals such as Vaccine and Psychiatry.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Gal Noyman Veksler invests in
Stages Gal Noyman Veksler invests in
Countries Gal Noyman Veksler invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Wellness 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
- Mental Health 1 (33%)
- Pharmaceutical 1 (33%)
Stage
- Seed 1 (33%)
- Pre-Seed 1 (33%)
- Series A 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $17M / Seed / Mar 31, 2026 | ||
| PhaseV is creating tools and cutting-edge statistical approaches to transform trial design, execution, and analysis. PhaseV recognizes hidden signals in clinical data and extracts actionable insights to help determine the best next moves. The company's technology provides optimal adaptive clinical trial design and closed-loop execution,enhancing efficiency and success rates. PhaseV is developing clinical trial paradigm shifts in order to provide novel therapies to more people in a more precise and efficient manner. | $50M / Series A / May 13, 2025 | ||
| Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $8M / Pre-Seed / Nov 19, 2024 |
Co-Investors
About LionBird
LionBird is a Tel Aviv- and Chicago-based venture capital firm investing in early-stage software companies operating in the healthcare, commerce, and enterprise sectors. Founded in 2012, LionBird has developed an investment strategy around early-stage startups that leverages online technology to re-imagine traditional offline business processes andmodels.
LionBird Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chaim Friedman
Founding Partner
|
|||
Ed Michael
Managing Partner
|
|||
Eric Fenster
Solo Legal Counsel / Partner
|
|||
|
Gal Noyman Veksler
Principal
|
|||
Itschak Friedman
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gal Noyman Veksler invest in?
Gal Noyman Veksler invests primarily in Wellness, Health Care and Therapeutics startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gal Noyman Veksler?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gal Noyman Veksler last invest?
The most recent investment recorded for Gal Noyman Veksler closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
